Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
-
Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET
-
管理層將於美國東部時間2024年5月9日星期四上午 8:30 主持電話會議
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, May 9, 2024, to report its first quarter 2024 financial results and provide an update on business progress.
新澤西州弗洛勒姆公園，2024年4月29日（GLOBE NEWSWIRE）——專注於開發和商業化胃腸道疾病新療法的生物製藥公司Phathom Pharmicals, Inc.（納斯達克股票代碼：PHAT）今天宣佈，將在美國東部時間2024年5月9日星期四上午8點30分舉辦網絡直播，報告其2024年第一季度財務業績並提供最新業務進展。
A live webcast and additional information about the presentation can be accessed on the News & Events section of the Phathom website at A recording will be available for 90 days following the conclusion of the meeting.
可以在Phathom網站的 “新聞與活動” 部分訪問網絡直播和有關演示的其他信息。會議結束後的90天內將提供錄像。
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA (vonoprazan) tablets for the treatment of Erosive GERD and relief of related heartburn in adults, in addition to VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the Company's website at and follow the Company on LinkedIn and X.
關於 Phathom 製藥公司
Phathom Pharmaceuticals是一家生物製藥公司，專注於胃腸道疾病新療法的開發和商業化。Phathom已獲得vonoprazan的獨家使用許可，vonoprazan是一種同類首創的鉀競爭性酸阻滯劑（PCAB），目前在美國以VOQUEZNA的名義銷售 （vonoprazan）片劑除VOQUEZNA外，還用於治療侵蝕性胃食管反流病和緩解成人相關胃灼熱 三重公園 （沃諾普拉贊片劑、阿莫西林膠囊、克拉黴素片劑）和 VOQUEZNA 雙包 （沃諾普贊片劑，阿莫西林膠囊）用於治療 幽門螺桿菌 成人感染。有關 Phathom 的更多信息，請訪問公司網站，並在 LinkedIn 和 X 上關注該公司。
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
媒體聯繫人
尼克·貝內代託
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
投資者聯繫人
埃裏克·西奧裏利
1-877-742-8466
ir@phathompharma.com
2024 Phathom Pharmaceuticals. All rights reserved.
2024 Phathom 製藥。版權所有。
譯文內容由第三人軟體翻譯。